UK markets closed

Ocuphire Pharma, Inc. (R3X1.F)

Frankfurt - Frankfurt Delayed price. Currency in EUR
Add to watchlist
1.8180+0.1220 (+7.19%)
At close: 09:55PM CEST
Show:
Balance sheet
Cash flow
Annual

Income statement

Currency in USD. All numbers in thousands
Breakdown
ttm
31/12/2023
31/12/2022
31/12/2021
31/12/2020
Total revenue
19,049
19,049
39,850
589
0
Operating expenses
Research development
17,653
17,653
14,355
15,173
6,648
Selling general and administrative
11,959
11,959
7,269
8,121
2,818
Total operating expenses
29,612
29,612
21,624
23,294
9,466
Operating income or loss
-10,563
-10,563
18,226
-22,705
-9,466
Interest expense
0
0
9
2
6,847
Total other income/expenses net
1,917
1,917
-14
-33,986
-8,307
Income before tax
-9,974
-9,974
18,203
-56,693
-24,620
Income tax expense
12
12
315
0
0
Income from continuing operations
-9,986
-9,986
17,888
-56,693
-24,620
Net income
-9,986
-9,986
17,888
-56,693
-24,620
Net income available to common shareholders
-9,986
-9,986
17,888
-56,693
-24,620
Basic EPS
1.47
-0.46
0.90
-3.82
-5.28
Diluted EPS
1.44
-0.46
0.87
-3.82
-5.28
Basic average shares
21,042
21,590
19,931
14,853
4,661
Diluted average shares
21,708
21,590
20,597
14,853
4,661